[Diagnosis and treatment of pulmonary aspergillosis. Role of voriconazole (discussion)].
Kohno
Shigeru
S
Ogawa
Kenji
K
Kurashima
Aatsuyuki
A
Niki
Yoshihito
Y
Maesaki
Shigefumi
S
D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000946:Antigens, Fungal / Q000097:blood; D001228:Aspergillosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008172:Lung Diseases, Fungal / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D017563:Lung Diseases, Interstitial / Q000150:complications; D008351:Mannans / Q000276:immunology; D017410:Practice Guidelines as Topic; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012698:Serologic Tests; D014230:Triazoles / Q000008:administration & dosage* / Q000009:adverse effects; D065819:Voriconazole
D000935:Antifungal Agents; D000946:Antigens, Fungal; D015415:Biomarkers; D008351:Mannans; D011743:Pyrimidines; D014230:Triazoles; C012990:galactomannan; D007073:Immunoglobulin E; D065819:Voriconazole; D005690:Galactose